Narrative Review of the Role of Patient-Reported Outcomes and Inhaler Handling Errors in the Control of Asthma and COPD

• Published in: Current allergy and asthma reports Vol. 22; no. 11; pp. 151 - 161
• Main Authors: De Simón Gutiérrez, Raúl, Castro, Raúl Piedra
• Format: Journal Article
• Language: English
• Published: New York Springer US 01.11.2022; Springer Nature B.V
• Subjects: Administration, Inhalation; Allergology; Asthma; Asthma (V Ortega; Asthma (V Ortega, Section Editor); Asthma - drug therapy; Bronchodilator Agents - therapeutic use; Budesonide, Formoterol Fumarate Drug Combination - therapeutic use; Chronic obstructive pulmonary disease; Clinical outcomes; Dry Powder Inhalers; Humans; Inhalers; Medicine; Medicine & Public Health; Patient Reported Outcome Measures; Pulmonary Disease, Chronic Obstructive - drug therapy; Quality of Life; Section Editor; Topical Collection on Asthma; Dry powder inhalers; Inhaler error; Spiromax; Patient-reported outcomes; Asthma; COPD
• ISSN: 1529-7322; 1534-6315
• DOI: 10.1007/s11882-022-01041-2

Purpose of Review Asthma and chronic obstructive pulmonary disease (COPD) are chronic respiratory diseases that remain uncontrolled in many patients, despite the wide range of therapeutic options available. This review analyzes the available clinical evidence on 3 budesonide/formoterol DPI devices, Spiromax ® , Turbuhaler ® , and Easyhaler ® , in terms of patient-reported outcomes (PROs), inhaler errors, and asthma and COPD control. Recent Findings The effectiveness of dry powder inhalers (DPI) depends largely on the device and the patient’s inhaler technique. Equally important are the patient’s perception of the inhaler and adherence. Given the high burden of these diseases, it is important that efforts be made to select the best DPI for each patient and to analyze the impact of these variables to help improve the health and quality of life of our patients. Summary This review provides a comprehensive overview of the present knowledge about PROs, inhaler handling errors, and asthma and COPD control achieved by Spiromax ® , Turbuhaler ® , and Easyhaler ® .